Van Hulzen Asset Management’s BioNTech BNTX Stock Holding History

Van Hulzen Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,001	Closed	-$601K	–	301
2022 Q4	$601K	Sell	4,001 -4,000	-50%	-$616K	0.07%	155
2022 Q3	$1.08M	Buy	8,001 +4,000	+100%	+$612K	0.13%	112
2022 Q2	$597K	Buy	+4,001	New	+$611K	0.07%	151
2022 Q1	–	Sell	-10,000	Closed	-$2.58M	–	312
2021 Q4	$2.58M	Buy	10,000 +5,200	+108%	+$1.42M	0.28%	73
2021 Q3	$1.31M	Buy	4,800 +1,088	+29%	+$346K	0.2%	84
2021 Q2	$831K	Buy	+3,712	New	+$700K	0.12%	100

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Van Hulzen Asset Management's BNTX Position: Q1 2023 in Review

Van Hulzen Asset Management sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 4,001 shares — an estimated $601K sold.

Van Hulzen Asset Management first reported a position in BNTX in Q2 2021 and held it in 6 quarters. The position peaked at $2.58M in Q4 2021. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Van Hulzen Asset Management reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Van Hulzen Asset Management sold 4,001 BioNTech shares in Q1 2023, an estimated $601K.
Van Hulzen Asset Management first reported a position in BioNTech in Q2 2021 and held it in 6 quarters.
Van Hulzen Asset Management's BioNTech position peaked at $2.58M in Q4 2021.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Van Hulzen Asset Management's 13F filing for Q1 2023, filed 28 Apr 2023.